This website is intended for healthcare professionals only.
The TAVI approach is a driver for organisational benefits, including shorter waiting lists, cuts to procedural times, increase in hospital capacity and shorter length of hospital stay.
The Edwards SAPIEN 3TM Transcatheter Heart Valve (THV) is eligible for use in all-risk patients,1–3 and it is expected that this will significantly increase the number of patients who will be treated with this minimally invasive procedure, with major implications for healthcare resource planning.4
Acute care institutions around the world have been reconfigured in response to the COVID-19 pandemic. As we enter the next phase, the priority will be addressing the backlog of patients whose care has been placed on hold. It has never been more critical that a hospital display maximum efficiency in delivering best clinical care to their patients – from shortening waiting lists and length of stay (LOS) to lowering re-hospitalisation rates. A key focus will be on patients with aortic stenosis.
There is a proven need to increase hospital efficiencies, including lowering in-hospital complications to improve outcomes for patients as well as increasing access to beds for other patients.5 More importantly, improved efficiency and lower complication rates will improve patient waiting times: studies have shown that increased patient times can affect patient mortality and morbidity while patients wait for intervention.6–8
What are the possible impacts on the hospital’s efficiencies?
Consolidating these hospital efficiencies, the results of the Vancouver 3M TAVI Study has demonstrated that a minimalist, streamlined TAVI pathway with the Edwards Lifesciences SAPIEN 3TM valve, with rapid remobilisation, allows for next-day discharge home, with reproducible, excellent safety and efficiency outcomes.18
Consequently, in the hospital, the TAVI-led efficiencies in the management of ssAS patients may have a significant economic benefit when the patient pathway is optimised. As demonstrated in the 3M TAVI study,18 optimising the patient pathway has benefits for the hospital such as early discharge and excellent patient outcomes, which ultimately, might lead to financial benefits, improved waiting lists and less demand for beds.
Optimising the patient pathway as outlined above will be crucial during and post-COVID-19. As all hospital resources will have been redistributed in order to tackle the current pandemic, a lot of patient care has been placed on hold. Tackling this backlog becomes of the utmost importance, and the TAVI-led efficiencies with the Edwards Lifesciences SAPIEN 3TM valve can support optimising hospital efficiency with this.